Last reviewed · How we verify
MultiGeneAngio
At a glance
| Generic name | MultiGeneAngio |
|---|---|
| Also known as | MGA |
| Sponsor | MultiGene Vascular Systems Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia (PHASE1, PHASE2)
- Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MultiGeneAngio CI brief — competitive landscape report
- MultiGeneAngio updates RSS · CI watch RSS
- MultiGene Vascular Systems Ltd. portfolio CI